Impact of acamprosate on plasma amyloid-β precursor protein in youth: A pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker

Journal of Psychiatric Research

Volumn 59, Issue , 2014, Pages 220-228

  Erickson, Craig A ^a   Ray, Balmiki ^b   Maloney, Bryan ^b   Wink, Logan K ^a   Bowers, Katherine ^a   Schaefer, Tori L ^a   McDougle, Christopher J ^c   Sokol, Deborah K ^b   Lahiri, Debomoy K ^b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Acamprosate; Amyloid precursor protein; Autism spectrum disorder; Biomarker; GABA; Glutamate

Indexed keywords

4 AMINOBUTYRIC ACID; ACAMPROSATE; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; ARIPIPRAZOLE; CLONIDINE; DEXAMPHETAMINE; FLUOXETINE; GLUTAMIC ACID; GUANFACINE; LISDEXAMFETAMINE; METHYLPHENIDATE; MIRTAZAPINE; OXCARBAZEPINE; PLACEBO; RISPERIDONE; TRAZODONE; VALPROIC ACID; ALPHA-SAPP PROTEIN, HUMAN; PEPTIDE FRAGMENT; TAURINE;

ADOLESCENT; ARTICLE; AUTISM; CHILD; CLINICAL ARTICLE; DISEASE ASSOCIATION; FEMALE; FRAGILE X SYNDROME; HUMAN; IDIOPATHIC DISEASE; INTELLIGENCE QUOTIENT; JUVENILE; MALE; PILOT STUDY; PROTEIN BLOOD LEVEL; PROTEIN PROCESSING; PROTEIN TARGETING; ANALOGS AND DERIVATIVES; BLOOD; CASE CONTROL STUDY; CHILD DEVELOPMENT DISORDERS, PERVASIVE; PRESCHOOL CHILD;

ADOLESCENT; AMYLOID BETA-PROTEIN PRECURSOR; CASE-CONTROL STUDIES; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; FEMALE; FRAGILE X SYNDROME; HUMANS; MALE; PEPTIDE FRAGMENTS; PILOT PROJECTS; TAURINE;

EID: 84908345598     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2014.07.011     Document Type: Article

References (76)

1. Albright C.F., Dockens R.C., Meredith J.E., Olson R.E., Slemmon R., Lentz K.A., et al. Pharmacodynamics of selective inhibition of gamma-secretase by avagacestat. JPharmacol Exp Ther 2013, 344:686-695. 10.1124/jpet.112.199356.
2. Alley G.M., Bailey J.A., Chen D., Ray B., Puli L.K., Tanila H., et al. Memantine lowers amyloid-beta peptide levels in neuronal cultures and in APP/PS1 transgenic mice. JNeurosci Res 2010, 88(1):143-154.
3. Aman M.G., Singh N.N., Stewart A.W., Field C.J. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 1985, 5:485-491.
4. Aylward E.H., Minshew N.J., Goldstein G., Honeycutt N.A., Augustine A.M., Yates K.O., et al. Diagnostic and statistical manual of mental disorders 2000, Text Revision, American Psychiatric Association, Washington, D.C. Four Edition.
5. American_Psychiatric_Association Diagnostic and statistical manual 2013, DSM-5, American Psychiatric Publishing, Washington, D.C. 5th ed.
6. Aylward E.H., Minshew N.J., Field K., Sparks B.F., Singh N. Effects of age on brain volume and head circumference in autism. Neurology 2002, 59:175-183.
7. Aylward E.H., Minshew N.J., Goldstein G., Honeycutt N.A., Augustine A.M., Yates K.O., et al. MRI volumes of amygdala and hippocampus in non-mentally retarded autistic adolescents and adults. Neurology 1999, 53:2145-2150.
8. Bagni C., Greenough W.T. From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome. Nat Rev Neurosci 2005, 6:376-387. nrn1667 [pii]. 10.1038/nrn1667.
9. Bailey A.R., Giunta B.N., Obregon D., Nikolic W.V., Tian J., Sanberg C.D., et al. Peripheral biomarkers in Autism: secreted amyloid precursor protein-alpha as a probable key player in early diagnosis. Int J Clin Exp Med 2008, 1:338-344.
10. Bailey J.A., Ray B., Greig N.H., Lahiri D.K. Rivastigmine lowers Abeta and increases sAPPalpha levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons. PLoS One 2011, 6:e21954. 10.1371/journal.pone.0021954.
11. Barger S.W., Harmon A.D. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature 1997, 388:878-881. 10.1038/42257.
12. Bear M.F. Therapeutic implications of the mGluR theory of fragile X mental retardation. Genes Brain Behav 2005, 4:393-398. GBB135 [pii]. 10.1111/j.1601-183X.2005.00135.x.
13. Bear M.F., Huber K.M., Warren S.T. The mGluR theory of fragile X mental retardation. Trends Neurosci 2004, 27:370-377. S0166223604001328 [pii]. 10.1016/j.tins.2004.04.009.
14. Blednov Y.A., Adron Harris R. Metabotropic glutamate receptor 5 (mGluR5) regulation of ethanol sedation, dependence and consumption: relationship to acamprosate actions. Int J Neuropsychopharmacol 2008, 11:775-793. S1461145708008584 [pii]. 10.1017/S1461145708008584.
15. Clifford S., Dissanayake C., Bui Q.M., Huggins R., Taylor A.K., Loesch D.Z. Autism spectrum phenotype in males and females with fragile X full mutation and premutation. JAutism Dev Disord 2007, 37:738-747. 10.1007/s10803-006-0205-z.
16. Constantino J.N., Davis S.A., Todd R.D., Schindler M.K., Gross M.M., Brophy S.L., et al. Validation of a brief quantitative measure of autistic traits: comparison of the social responsiveness scale with the autism diagnostic interview-revised. JAutism Dev Disord 2003, 33:427-433.
17. Courchesne E., Carper R., Akshoomoff N. Evidence of brain overgrowth in the first year of life in autism. JAMA 2003, 290:337-344. doi:10.1001/jama.290.3.337 290/3/337 [pii].
18. Courchesne E., Karns C.M., Davis H.R., Ziccardi R., Carper R.A., Tigue Z.D., et al. Unusual brain growth patterns in early life in patients with autistic disorder: an MRI study. Neurology 2001, 57:245-254.
19. Courchesne E., Pierce K. Brain overgrowth in autism during a critical time in development: implications for frontal pyramidal neuron and interneuron development and connectivity. Int J Dev Neurosci 2005, 23:153-170. S0736-5748(05)00004-3 [pii]. 10.1016/j.ijdevneu.2005.01.003.
20. Darnell J.C., Van Driesche S.J., Zhang C., Hung K.Y., Mele A., Fraser C.E., et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 2011, 146:247-261. 10.1016/j.cell.2011.06.013.
21. Davidovitch M., Patterson B., Gartside P. Head circumference measurements in children with autism. JChild Neurol 1996, 11:389-393.
22. De Rubeis S., Bagni C. Fragile X mental retardation protein control of neuronal mRNA metabolism: insights into mRNA stability. Mol Cell Neurosci 2010, 43:43-50. S1044-7431(09)00219-X [pii]. 10.1016/j.mcn.2009.09.013.
23. DuPaul G., Power T., Anastopaulus A., Reid R. ADHD rating scale IV: checklists, norms, and clinical interpretation 1998, Guilford, New York.
24. Erickson C.A., Early M., Stigler K.A., Wink L.K., Mullett J.E., McDougle C.J. An open-label naturalistic pilot study of acamprosate in youth with autistic disorder. JChild Adolesc Psychopharmacol 2011, 21:565-569. 10.1089/cap.2011.0034.
25. Erickson C.A., Mullett J.E., McDougle C.J. Brief report: acamprosate in fragile X syndrome. Jautism Dev Disord 2010, 40:1412-1416. 10.1007/s10803-010-0988-9.
26. Erickson C.A., Wink L.K., Early M.C., Stiegelmeyer E., Mathieu-Frasier L., Patrick V., et al. Brief report: pilot single-blind placebo lead-in study of acamprosate in youth with autistic disorder. JAutism Dev Disord 2013, 10.1007/s10803-013-1943-3.
27. Erickson C.A., Wink L.K., Ray B., Early M.C., Stiegelmeyer E., Mathieu-Frasier L., et al. Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. Psychopharmacology 2013, 10.1007/s00213-013-3022-z.
28. Fatemi S.H., Folsom T.D., Kneeland R.E., Yousefi M.K., Liesch S.B., Thuras P.D. Impairment of fragile X mental retardation protein-metabotropic glutamate receptor 5 signaling and its downstream cognates ras-related C3 botulinum toxin substrate 1, amyloid beta A4 precursor protein, striatal-enriched protein tyrosine phosphatase, and homer 1, in autism: a postmortem study in cerebellar vermis and superior frontal cortex. Mol Autism 2013, 4:21. 10.1186/2040-2392-4-21.
29. Garcia-Nonell C., Ratera E.R., Harris S., Hessl D., Ono M.Y., Tartaglia N., et al. Secondary medical diagnosis in fragile X syndrome with and without autism spectrum disorder. Am J Med Genet A 2008, 146A:1911-1916. 10.1002/ajmg.a.32290.
30. Greig N.H., Utsuki T., Ingram D.K., Wang Y., Pepeu G., Scali C., et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc Natl Acad Sci U S A 2005, 102:17213-17218. 10.1073/pnas.0508575102.
31. Gupta T., Syed Y.M., Revis A.A., Miller S.A., Martinez M., Cohn K.A., et al. Acute effects of acamprosate and MPEP on ethanol Drinking-in-the-Dark in male C57BL/6J mice. Alcohol Clin Exp Res 2008, 32:1992-1998. ACER787 [pii]. 10.1111/j.1530-0277.2008.00787.x.
32. Guy W. ECDEU assessment manual for psychopharmacology 1976, Publication No. 76-338, U.S. DHEW, NIMH, Washington, DC.
33. Harris B.R., Prendergast M.A., Gibson D.A., Rogers D.T., Blanchard J.A., Holley R.C., et al. Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcohol Clin Exp Res 2002, 26:1779-1793. 10.1097/01.ALC.0000042011.99580.98.
34. Hatton D.D., Sideris J., Skinner M., Mankowski J., Bailey D.B., Roberts J., et al. Autistic behavior in children with fragile X syndrome: prevalence, stability, and the impact of FMRP. Am J Med Genet A 2006, 140A:1804-1813. 10.1002/ajmg.a.31286.
35. Hazlett H.C., Poe M.D., Gerig G., Styner M., Chappell C., Smith R.G., et al. Early brain overgrowth in autism associated with an increase in cortical surface area before age 2 years. Arch Gen Psychiatry 2011, 68:467-476. 10.1001/archgenpsychiatry.2011.39.
36. Hazlett H.C., Poe M.D., Lightbody A.A., Styner M., MacFall J.R., Reiss A.L., et al. Trajectories of early brain volume development in fragile X syndrome and autism. JAm Acad Child Adolesc Psychiatry 2012, 51:921-933. 10.1016/j.jaac.2012.07.003.
37. Jolly-Tornetta C., Gao Z.Y., Lee V.M., Wolf B.A. Regulation of amyloid precursor protein secretion by glutamate receptors in human NTERA 2 neurons. JBiol Chem 1998, 273:14015-14021.
38. Kaufmann W.E., Cortell R., Kau A.S., Bukelis I., Tierney E., Gray R.M., et al. Autism spectrum disorder in fragile X syndrome: communication, social interaction, and specific behaviors. Am J Med Genet A 2004, 129A:225-234. 10.1002/ajmg.a.30229.
39. Kosinovsky B., Hermon S., Yoran-Hegesh R., Golomb A., Senecky Y., Goez H., et al. The yield of laboratory investigations in children with infantile autism. JNeural Transm 2005, 112:587-596. 10.1007/s00702-004-0198-8.
40. Kotlinska J., Bochenski M. The influence of various glutamate receptors antagonists on anxiety-like effect of ethanol withdrawal in a plus-maze test in rats. Eur J Pharmacol 2008, 598:57-63. S0014-2999(08)00970-9 [pii]. 10.1016/j.ejphar.2008.09.026.
41. Lahiri D.K., Farlow M.R., Sambamurti K. The secretion of amyloid beta-peptides is inhibited in the tacrine-treated human neuroblastoma cells. Brain Res Mol Brain Res 1998, 62:131-140.
42. Lahiri D.K., Farlow M.R., Sambamurti K., Greig N.H., Giacobini E., Schneider L.S. Acritical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Curr Drug Targets 2003, 4:97-112.
43. Lahiri D.K., Lewis S., Farlow M.R. Tacrine alters the secretion of the beta-amyloid precursor protein in cell lines. JNeurosci Res 1994, 37:777-787. 10.1002/jnr.490370612.
44. Lahiri D.K., Long J.M., Ray B., Sokol D.K. Biochemical evidence for the dysregulation of Alzheimer's amyloid precursor protein (APP) expression and metabolism in fragile X syndrome (FXS) and severe autism. Paper presented at the Society of Biological Psychiatry, New Orleans, Louisiana, May 12, 2011 2011.
45. Lahiri D.K., Maloney B., Long J.M., Greig N.H. Lessons from a BACE1 inhibitor trial: off-site but not off base. Alzheimers Dement 2014, S1552-5260(13)02917-8.
46. Lahiri D.K., Nall C., Chen D., Zaphiriou M., Morgan C., Nurnberger J.I. Developmental expression of the beta-amyloid precursor protein and heat-shock protein 70 in the cerebral hemisphere region of the rat brain. Ann N Y Acad Sci 2002, 965:324-333.
47. Lahiri D.K., Sokol D.K., Erickson C., Ray B., Ho C.Y., Maloney B. Autism as early neurodevelopmental disorder: evidence for an sAPPalpha-mediated anabolic pathway. Front Cell Neurosci 2013, 7:94. 10.3389/fncel.2013.00094.
48. Lee E.K., et al. hnRNP C promotes APP translation by competing with FMRP for APP mRNA recruitment to P bodies. Nat Struct Mol Biol 2010, 17:732-739. 10.1038/nsmb.1815.
49. Mann K., Kiefer F., Spanagel R., Littleton J. Acamprosate: recent findings and future research directions. Alcohol Clin Exp Res 2008, 32:1105-1110. ACER690 [pii]. 10.1111/j.1530-0277.2008.00690.x.0. ACER690 [pii].
50. Mattson M.P. Secreted forms of beta-amyloid precursor protein modulate dendrite outgrowth and calcium responses to glutamate in cultured embryonic hippocampal neurons. JNeurobiol 1994, 25:439-450. 10.1002/neu.480250409.
51. Mattson M.P. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev 1997, 77:1081-1132.
52. Mattson M.P., Furukawa K. Signaling events regulating the neurodevelopmental triad. Glutamate and secreted forms of beta-amyloid precursor protein as examples. Perspect Dev Neurobiol 1998, 5:337-352.
53. Mayer S., Harris B., Gibson D.A., Blanchard J., Prendergast M.A., Holley R.C., et al. Acamprosate has no effect on NMDA-induced toxicity but reduces toxicity induced by spermidine or by changing the medium in organotypic hippocampal slice cultures from rat. Alcohol Clin Exp Res 2002, 26:655-662.
54. McCaffery P., Deutsch C.K. Macrocephaly and the control of brain growth in autistic disorders. Prog Neurobiol 2005, 77:38-56. S0301-0082(05)00118-8 [pii]. 10.1016/j.pneurobio.2005.10.005.
55. McDougle C.J., Erickson C.A., Stigler K.A., Posey D.J. Neurochemistry in the pathophysiology of autism. JClin Psychiatry 2005, 66(Suppl.10):9-18.
56. McGrew S.G., Peters B.R., Crittendon J.A., Veenstra-Vanderweele J. Diagnostic yield of chromosomal microarray analysis in an autism primary care practice: which guidelines to implement?. JAutism Dev Disord 2012, 42:1582-1591. 10.1007/s10803-011-1398-3.
57. Mullan M., Crawford F. Genetic and molecular advances in Alzheimer's disease. Trends Neurosci 1993, 16:398-403.
58. Naassila M., Hammoumi S., Legrand E., Durbin P., Daoust M. Mechanism of action of acamprosate. Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain. Alcohol Clin Exp Res 1998, 22:802-809. doi:00000374-199806000-00005 [pii].
59. Pierrefiche O., Daoust M., Naassila M. Biphasic effect of acamprosate on NMDA but not on GABAA receptors in spontaneous rhythmic activity from the isolated neonatal rat respiratory network. Neuropharmacol 2004, 47:35-45. doi:10.1016/j.neuropharm.2004.03.004 S002839080400070X [pii].
60. Priller C., Bauer T., Mitteregger G., Krebs B., Kretzschmar H.A., Herms J. Synapse formation and function is modulated by the amyloid precursor protein. JNeurosci 2006, 26:7212-7221. 26/27/7212 [pii]. 10.1523/JNEUROSCI.1450-06.2006.
61. Ray B., Long J.M., Sokol D.K., Lahiri D.K. Increased secreted amyloid precursor protein-alpha (sAPPalpha) in severe autism: proposal of a specific, anabolic pathway and putative biomarker. PLoS One 2011, 6:e20405. 10.1371/journal.pone.0020405.
62. Reilly M.T., Lobo I.A., McCracken L.M., Borghese C.M., Gong D., Horishita T., et al. Effects of acamprosate on neuronal receptors and ion channels expressed in Xenopus oocytes. Alcohol Clin Exp Res 2008, 32:188-196. ACER569 [pii]. 10.1111/j.1530-0277.2007.00569.x.
63. Schubert D., Jin L.W., Saitoh T., Cole G. The regulation of amyloid beta protein precursor secretion and its modulatory role in cell adhesion. Neuron 1989, 3:689-694. doi:0896-6273(89)90237-7 [pii].
64. Sokol D.K., Chen D., Farlow M.R., Dunn D.W., Maloney B., Zimmer J.A., et al. High levels of Alzheimer beta-amyloid precursor protein (APP) in children with severely autistic behavior and aggression. JChild Neurol 2006, 21:444-449.
65. Sokol D.K., Maloney B., Long J.M., Ray B., Lahiri D.K. Autism, Alzheimer disease, and fragile X: APP, FMRP, and mGluR5 are molecular links. Neurology 2011, 76:1344-1352. 10.1212/WNL.0b013e3182166dc7.
66. Sparks B.F., Friedman S.D., Shaw D.W., Aylward E.H., Echelard D., Artru A.A., et al. Brain structural abnormalities in young children with autism spectrum disorder. Neurology 2002, 59:184-192.
67. Stein T.D., Johnson J.A. Genetic programming by the proteolytic fragments of the amyloid precursor protein: somewhere between confusion and clarity. Rev Neurosci 2003, 14:317-341.
68. Tajima Y., Ishikawa M., Maekawa K., Murayama M., Senoo Y., Nishimaki-Mogami T., et al. Lipidomic analysis of brain tissues and plasma in a mouse model expressing mutated human amyloid precursor protein/tau for Alzheimer's disease. Lipids Health Dis 2013, 12:68. 10.1186/1476-511X-12-68.
69. Turner P.R., O'Connor K., Tate W.P., Abraham W.C. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol 2003, 70:1-32.
70. Veneri M., Zalfa F., Bagni C. FMRP and its target RNAs: fishing for the specificity. Neuroreport 2004, 15:2447-2450. doi:00001756-200411150-00002 [pii].
71. Wegiel J., et al. Abnormal intracellular accumulation and extracellular Abeta deposition in idiopathic and Dup15q11.2-q13 autism spectrum disorders. PLoS One 2012, 7:e35414. 10.1371/journal.pone.0035414.
72. Westmark C.J., Malter J.S. FMRP mediates mGluR5-dependent translation of amyloid precursor protein. PLoS Biol 2007, 5:e52. 1544-9173-5-3-e52 [pii]. 10.1371/journal.pbio.0050052.
73. Westmark C.J., et al. Reversal of fragile X phenotypes by manipulation of AbetaPP/Abeta levels in Fmr1KO mice. PLoS One 2011, 6:e26549. 10.1371/journal.pone.0026549.
74. Young-Pearse T.L., Bai J., Chang R., Zheng J.B., LoTurco J.J., Selkoe D.J. Acritical function for beta-amyloid precursor protein in neuronal migration revealed by in utero RNA interference. JNeurosci 2007, 27:14459-14469.
75. Zalfa F., Giorgi M., Primerano B., Moro A., Di Penta A., Reis S., et al. The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses. Cell 2003, 112:317-327. doi:S0092867403000795 [pii].
76. Zou K., Liu J., Zhu N., Lin J., Liang Q., Brown W.T., et al. Identification of FMRP-associated mRNAs using yeast three-hybrid system. Am J Med Genet B Neuropsychiatr Genet 2008, 147B:769-777. 10.1002/ajmg.b.30678.